| | ior P™ | |
|----|--------|---|
| | Pate. | |
| ٧. | | _ |
| ~~ | AL-nr | |

| | | | | THE STREET STREET OF COMMERCE | | |
|-------|-----------------------|-----------------|------------------------|-------------------------------|--|--|
| | · | | | COMPLETE IF KNOWN | | |
|] | INFORMATION D | ISCLOSURE | Application Number | 09/445,054 | | |
| S | STATEMENT BY A | APPIRCENT | Filing Date | December 1, 1999 | | |
| _ | / | (C) \(\omega\) | First Named Inventor | N. Rosen, et. al. | | |
| | (use as many sheets a | NO 1 70M L | Group Art Unit | | | |
| | | | Examiner Name | | | |
| Sheet | 1 1 | OF ENTE TONOSAN | Attorney Docket Number | 10063VP | | |

| | | | U.S. P. | ATENT DOCUMENTS | |
|-----------------------|-------------|---------------------------------------|----------------------------|---|--|
| Examiner Initials* | Cite No. | U.S. Patent Document Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| B | | 5,912,154 | | Ferro-Novick, et al. | 06/15/1999 |
| 2 | | 5,856,326 | | Anthony, et al. | 01/05/1999 |
| | | | | | |
| | | | | | |
| | | | +- | | 7 |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | - | | |
| | | | | | |
| | | | | | |
| | | | - | | |
| | | | | 1 | |
| | | | | | |
| _ | | · · · · · · · · · · · · · · · · · · · | _ | ÷ | |
| \rightarrow | | i | | | |
| | | | | | |
| | | | | | |

| | | | FOREI | GN PATEN | T DOCUMENTS | | |
|-----------------------|-------------|---------------|------------------------|----------------------------|--|---------------------------|--|
| Examiner Initials* | Cite No. | | Foreign Patent Documen | | Name of Detailed and April | Date of Publication of | |
| | | Office Number | | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY | |
| | × | EP | 0 856 315 A1 | | Banyu Phameceutical Co., LTD. | 02/20/1997 | |
| | × | EP | 0 618 221 A2 | | Bristol-Myers Squibb Company | 05/10/1994 | |
| | <u> ۲</u> | | EP 0 670 314 A1 | | Kyowa Hakko Kogyo Co., LTD. | 03/30/1995 | |
| | × | PCT | WO 97/17070 | | University of Pittsburgh | 05/15/1997 | |
| | <u> </u> | EP | 0 456 180 A1 | | E. R. Squibb & Sons, Inc. | 11/13/1991 | |
| | | РСТ | WO 97/01275 | | Banyu Phameceutical Co., LTD. | 01/16/1997 | |
| | × | 20 | waies | | | | |
| | | | V. Jane | | | | |

| Examiner Signature (Jun) - [Jun] | Date Considered | 10/4/01 |
|----------------------------------|--------------------|---------|

| | | | | | ,str | d Trademark Office, U.S. DEPARTMENT OF COMMERC | |
|-------|------------------|---------|---------------------|------------------------|-------------------|--|--|
| | | | _ | | COMPLETE IF KNOWN | | |
| 1 | NFORMATIO | N DIS | SCLOSURE | Application Number | 09/445 | ,054 | |
| S | STATEMENT I | RV AI | PPI JCANT | Filing Date | Decem | ber 1, 1999 | |
| | | | | First Named Inventor | N. Ros | en, et. al. | |
| | luse as many sh | eets as | necessary) 7 2001 2 | Group Art Unit | | | |
| | (use us many sne | eeis us | P. S. | Examiner Name | | | |
| Sheet | 2 | of | STOR AND AND THE | Attorney Docket Number | 199621 | ΥP | |

| | OTHER NON PATENT LITERATURE DOCUMENTS | | | | | |
|-----------------------|---------------------------------------|---|--|--|--|--|
| Examiner initials* | Cite No. | | | | | |
| | 7 | Moasser, et al., Farnesyl transferase inhibitors cause enchanced mitotic sensitivity to taxol and epothilones, February 1998, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1369-1374Molecular Pharmacology, Vol. 47, pp. 1106-1111 (1995) | | | | |
| | 7 | Danesi, Paclitaxel (Taxol) Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human Prostate Cancer Cells, 1995, Molecular Pharmacology, Vol 47, pp. 1106-1111 | | | | |
| | | | | | | |
| | Y | no upier | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Examiner Signature | 7 | Date 10/4/01 | | | | |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.